Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
28
MAYNF Quote, Financials, Valuation and Earnings
Last price:
$2.36
Seasonality move
:
-4.45%
Day range:
$2.36 - $2.36
52-week range:
$2.36 - $4.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.72x
P/B ratio:
0.96x
Volume:
--
Avg. volume:
3.7K
1-year change:
-21.52%
Market cap:
$191.7M
Revenue:
$264.3M
EPS (TTM):
-$0.76
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MAYNF
Mayne Pharma Group Ltd.
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $12.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $19.01 |
|
MESO
Mesoblast Ltd.
|
$24.8M | -- | -100% | -- | $35.00 |
|
PPCB
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MAYNF
Mayne Pharma Group Ltd.
|
$2.36 | -- | $191.7M | -- | $0.00 | 0% | 0.72x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.09 | $12.00 | $56M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$2.63 | $9.50 | $382.8M | -- | $0.00 | 0% | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
$10.87 | $19.01 | $18.2M | -- | $0.00 | 0% | 491.15x |
|
MESO
Mesoblast Ltd.
|
$19.48 | $35.00 | $2.5B | -- | $0.00 | 0% | 136.71x |
|
PPCB
|
$11.98 | -- | $158.1K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MAYNF
Mayne Pharma Group Ltd.
|
8.2% | -1.292 | -- | 1.06x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -1.575 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.640 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 5.445 | 5.57% | 0.07x |
|
MESO
Mesoblast Ltd.
|
-- | 0.345 | -- | -- |
|
PPCB
|
-- | 4.794 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MAYNF
Mayne Pharma Group Ltd.
|
-- | -- | -24.87% | -26.72% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
MESO
Mesoblast Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PPCB
|
-- | -$290.8K | -- | -- | -- | -$235.5K |
Mayne Pharma Group Ltd. vs. Competitors
-
Which has Higher Returns MAYNF or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Mayne Pharma Group Ltd.'s net margin of --. Mayne Pharma Group Ltd.'s return on equity of -26.72% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MAYNFMayne Pharma Group Ltd.-- -- $302.3M ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About MAYNF or ATHE?
Mayne Pharma Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $12.00 which suggests that it could grow by 288.35%. Given that Alterity Therapeutics Ltd. has higher upside potential than Mayne Pharma Group Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Mayne Pharma Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MAYNFMayne Pharma Group Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.0 0 0 -
Is MAYNF or ATHE More Risky?
Mayne Pharma Group Ltd. has a beta of 1.872, which suggesting that the stock is 87.241% more volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.023, suggesting its less volatile than the S&P 500 by 97.656%.
-
Which is a Better Dividend Stock MAYNF or ATHE?
Mayne Pharma Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mayne Pharma Group Ltd. pays -- of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAYNF or ATHE?
Mayne Pharma Group Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Mayne Pharma Group Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Mayne Pharma Group Ltd.'s price-to-earnings ratio is -- while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mayne Pharma Group Ltd. is 0.72x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAYNFMayne Pharma Group Ltd.0.72x -- -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns MAYNF or IMMP?
Immutep Ltd. has a net margin of -- compared to Mayne Pharma Group Ltd.'s net margin of --. Mayne Pharma Group Ltd.'s return on equity of -26.72% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MAYNFMayne Pharma Group Ltd.-- -- $302.3M IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About MAYNF or IMMP?
Mayne Pharma Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 261.22%. Given that Immutep Ltd. has higher upside potential than Mayne Pharma Group Ltd., analysts believe Immutep Ltd. is more attractive than Mayne Pharma Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MAYNFMayne Pharma Group Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is MAYNF or IMMP More Risky?
Mayne Pharma Group Ltd. has a beta of 1.872, which suggesting that the stock is 87.241% more volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.925, suggesting its more volatile than the S&P 500 by 92.469%.
-
Which is a Better Dividend Stock MAYNF or IMMP?
Mayne Pharma Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mayne Pharma Group Ltd. pays -- of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAYNF or IMMP?
Mayne Pharma Group Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Mayne Pharma Group Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Mayne Pharma Group Ltd.'s price-to-earnings ratio is -- while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mayne Pharma Group Ltd. is 0.72x versus -- for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAYNFMayne Pharma Group Ltd.0.72x -- -- -- IMMPImmutep Ltd.-- -- -- --
-
Which has Higher Returns MAYNF or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Mayne Pharma Group Ltd.'s net margin of --. Mayne Pharma Group Ltd.'s return on equity of -26.72% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital MAYNFMayne Pharma Group Ltd.-- -- $302.3M KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About MAYNF or KZIA?
Mayne Pharma Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $19.01 which suggests that it could grow by 75.2%. Given that Kazia Therapeutics Ltd. has higher upside potential than Mayne Pharma Group Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Mayne Pharma Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MAYNFMayne Pharma Group Ltd.0 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is MAYNF or KZIA More Risky?
Mayne Pharma Group Ltd. has a beta of 1.872, which suggesting that the stock is 87.241% more volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.185%.
-
Which is a Better Dividend Stock MAYNF or KZIA?
Mayne Pharma Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mayne Pharma Group Ltd. pays -- of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAYNF or KZIA?
Mayne Pharma Group Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Mayne Pharma Group Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Mayne Pharma Group Ltd.'s price-to-earnings ratio is -- while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mayne Pharma Group Ltd. is 0.72x versus 491.15x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAYNFMayne Pharma Group Ltd.0.72x -- -- -- KZIAKazia Therapeutics Ltd.491.15x -- -- --
-
Which has Higher Returns MAYNF or MESO?
Mesoblast Ltd. has a net margin of -- compared to Mayne Pharma Group Ltd.'s net margin of --. Mayne Pharma Group Ltd.'s return on equity of -26.72% beat Mesoblast Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MAYNFMayne Pharma Group Ltd.-- -- $302.3M MESOMesoblast Ltd.-- -- -- -
What do Analysts Say About MAYNF or MESO?
Mayne Pharma Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Mesoblast Ltd. has an analysts' consensus of $35.00 which suggests that it could grow by 79.67%. Given that Mesoblast Ltd. has higher upside potential than Mayne Pharma Group Ltd., analysts believe Mesoblast Ltd. is more attractive than Mayne Pharma Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings MAYNFMayne Pharma Group Ltd.0 0 0 MESOMesoblast Ltd.1 0 0 -
Is MAYNF or MESO More Risky?
Mayne Pharma Group Ltd. has a beta of 1.872, which suggesting that the stock is 87.241% more volatile than S&P 500. In comparison Mesoblast Ltd. has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.508%.
-
Which is a Better Dividend Stock MAYNF or MESO?
Mayne Pharma Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mesoblast Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mayne Pharma Group Ltd. pays -- of its earnings as a dividend. Mesoblast Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAYNF or MESO?
Mayne Pharma Group Ltd. quarterly revenues are --, which are smaller than Mesoblast Ltd. quarterly revenues of --. Mayne Pharma Group Ltd.'s net income of -- is lower than Mesoblast Ltd.'s net income of --. Notably, Mayne Pharma Group Ltd.'s price-to-earnings ratio is -- while Mesoblast Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mayne Pharma Group Ltd. is 0.72x versus 136.71x for Mesoblast Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAYNFMayne Pharma Group Ltd.0.72x -- -- -- MESOMesoblast Ltd.136.71x -- -- --
-
Which has Higher Returns MAYNF or PPCB?
has a net margin of -- compared to Mayne Pharma Group Ltd.'s net margin of --. Mayne Pharma Group Ltd.'s return on equity of -26.72% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MAYNFMayne Pharma Group Ltd.-- -- $302.3M PPCB-- -$0.00 -- -
What do Analysts Say About MAYNF or PPCB?
Mayne Pharma Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Mayne Pharma Group Ltd. has higher upside potential than , analysts believe Mayne Pharma Group Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings MAYNFMayne Pharma Group Ltd.0 0 0 PPCB0 0 0 -
Is MAYNF or PPCB More Risky?
Mayne Pharma Group Ltd. has a beta of 1.872, which suggesting that the stock is 87.241% more volatile than S&P 500. In comparison has a beta of 1.881, suggesting its more volatile than the S&P 500 by 88.104%.
-
Which is a Better Dividend Stock MAYNF or PPCB?
Mayne Pharma Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mayne Pharma Group Ltd. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MAYNF or PPCB?
Mayne Pharma Group Ltd. quarterly revenues are --, which are smaller than quarterly revenues of --. Mayne Pharma Group Ltd.'s net income of -- is lower than 's net income of -$354.3K. Notably, Mayne Pharma Group Ltd.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mayne Pharma Group Ltd. is 0.72x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MAYNFMayne Pharma Group Ltd.0.72x -- -- -- PPCB-- -- -- -$354.3K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
